Relmada Therapeutics GAAP EPS of -$0.27 misses by $0.13 [Seeking Alpha]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Seeking Alpha
Research and development expense for the three months ended December 31, 2025, totaled $8.1 million, compared to $11.0 million for the three months ended December 31, 2024, a decrease of $2.9 million. General and administrative expense for the three months ended December 31, 2025, totaled $12.3 million compared to $8.1 million for the three months ended December 31, 2024, an increase of approximately $4.2 million. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up More on Relmada Therapeutics Seeking Alpha's Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Therapeutics More Trending News
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.MarketBeat
- Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]Yahoo! Finance
- Relmada (RLMD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 3/19/26 - Miss
RLMD
Sec Filings
- 3/20/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/9/26 - Form 8-K
- RLMD's page on the SEC website